AFP and hepatocellular carcinoma: Three independent study groups underlined the prognostic value of AFP response at six weeks for the evaluation of atezolizumab/bevacizumab treatment efficacy [63,69,71], while both Iwamoto et al. and Komatsu et al. demonstrated that atezolizumab/bevacizumab can be effective for unresectable HCC, irrespective of the ALBI grade [66,67].